# Safety And Efficacy In Long Term Use Of Lyrica (Regulatory Post Marketing Commitment Plan)

> **NCT01279850** · — · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 891 (actual)

## Conditions studied

- Neuropathic Pain

## Interventions

- **DRUG:** Pregabalin (Lyrica) capsule

## Key facts

- **NCT ID:** NCT01279850
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 891 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01279850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01279850, "Safety And Efficacy In Long Term Use Of Lyrica (Regulatory Post Marketing Commitment Plan)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01279850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*